Clinical Research Directory

Inclusion Criteria: (I) Chinese Patients taking NOACs * In accordance with anticoagulation indications of NOACs, include prevention of thrombosis in non valvular atrial fibrillation, prevention and treatment of deep vein thrombosis / pulmonary embolism and prevention of thrombosis after knee / hip replacement; * More than 18 years of age, male or female; * Never received NOACs in a month and intend to take NOACs or have received NOACs for more than one week continuously; * sign informed consent. (II) Chinese Patients taking ticagrelor * With diagnosis of acute coronary syndrome (ACS), included unstable angina, non ST segment elevation myocardial infarction and ST segment elevation myocardial infarction; * More than 18 years of age, male or female; * Never received ticagrelor in a month and intend to take ticagrelor or have received ticagrelor for more than one week continuously# * sign informed consent. Exclusion Criteria: * With history of immunodeficiency disease, including positive HIV index; * Positive Hepatitis B surface antigen (HBsAg) and HCV index; * Combined therapy of CYP3A4 strong inhibitors and P-gp inhibitors (e.g., systemic pyrrole antifungal agents such as ketoconazole, itraconazole, voriconazole and posaconazole; human immunodeficiency virus (HIV) - protease inhibitors such as ritonavir), CYP3A4 strong inducers and P-gp inducers (e.g., rifampicin, phenytoin, phenobarbital, carbamazepine, St. John's Wort, etc.) in 14 days before treatment with NOACs; * Severe liver dysfunction and abnormal renal function; * Include contraindications of antithrombosis, such as hypersensitivity, active bleeding, moderate or severe liver disease, previous history of intracranial hemorrhage, gastrointestinal hemorrhage in the past 6 months and major operation within 30 days.